Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

British journal of clinical pharmacology·2026
Same author

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection.

Journal of the Royal Society, Interface·2026
Same author

Targeting dengue virus envelope protein: Insights from structural analysis and high-throughput screening.

Antiviral research·2026
Same author

Beyond assembly: functions of the coronavirus M protein.

Virology journal·2026
Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

7.0K

每日使用莫斯诺登维尔作为控制人类感染模型中的登革热预防.

Anna P Durbin1, Liesbeth Van Wesenbeeck2, Kristen K Pierce3

  • 1Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.

The New England journal of medicine
|November 26, 2025
PubMed
概括
此摘要是机器生成的。

高剂量的莫斯诺登维尔在人类感染模型中显著降低了登革热病毒3型RNA负载. 这种抗病毒药物显示出作为潜在的登革热治疗的希望,没有观察到严重的不良事件.

更多相关视频

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

19.0K
Experimental Viral Infection in Adult Mosquitoes by Oral Feeding and Microinjection
08:02

Experimental Viral Infection in Adult Mosquitoes by Oral Feeding and Microinjection

Published on: July 28, 2022

2.8K

相关实验视频

Last Updated: Jan 10, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

7.0K
Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

19.0K
Experimental Viral Infection in Adult Mosquitoes by Oral Feeding and Microinjection
08:02

Experimental Viral Infection in Adult Mosquitoes by Oral Feeding and Microinjection

Published on: July 28, 2022

2.8K

科学领域:

  • 病毒学 病毒学
  • 传染性疾病 传染性疾病
  • 抗病毒研究 抗病毒研究

背景情况:

  • 登革热影响全球一半的人口,没有可用的抗病毒治疗方法.
  • 目前的登革热预防依赖于载体控制和支持性护理.

研究的目的:

  • 在受控的人类感染模型中评估口服莫斯诺登维尔对3型登革热病毒 (DENV-3) 的疗效和安全性.
  • 为了确定莫斯诺登维尔对抗病毒活性的最佳剂量.

主要方法:

  • 一个2a期,双盲,随机试验,涉及健康的成年人,他们被挑战了低衰减的DENV-3菌株.
  • 参与者接受了低,中,或高剂量的口服莫斯诺登维尔,或安慰剂.
  • 主要终点:DENV-3 RNA负载 (log10 AUC D1-29);次要终点:安全性,药理动力学,病毒学和血清学特征.

主要成果:

  • 高剂量莫斯诺登维尔导致60%的参与者没有感染,而安慰剂为0%.
  • 在高剂量莫斯诺登维尔与安慰剂 (P<0.001) 相比,观察到显着较低的DENV-3RNA负载 (log10 AUC D1-29).
  • 没有报告严重的不良事件;病毒NS4B变异出现在mosnodenvir接受者中.

结论:

  • 高剂量口服莫斯诺登维尔在受控的人类感染模型中显著降低了DENV-3RNA负载.
  • 莫斯诺登维尔是安全的,耐受性很好,没有严重的不良事件.
  • 进一步调查mosnodenvir作为潜在的登革热治疗药物是有必要的.